Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis
Range Bound setup
Healthcare · Biotechnology
Sell if holding. Engine safety override at $3.52: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 35%; Below-average business quality; Negative price momentum.
Recursion Pharmaceuticals is a clinical-stage TechBio company using its AI-native Recursion OS platform for drug discovery spanning biology, chemistry, and clinical development. Revenue is primarily from funded R&D collaboration agreements with Roche/Genentech, Takeda, and... Read more
Sell if holding. Engine safety override at $3.52: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 35%; Below-average business quality; Negative price momentum. Chart setup: RSI 57 mid-range, Bollinger mid-band. Score 4.1/10, moderate confidence.
Passes 5/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 6d<=7d. Suitability: aggressive.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerRoche and Genentech, Takeda, and Bayer10-K Item 1A: 'our operating revenue has primarily been generated through funded research and development agreements with Roche and Genentech, Takeda, and Bayer'
Material Events(8-K, last 90d)
- 2026-03-25Item 5.02LOWVicki Goodman, M.D., appointed as Recursion's Chief Medical Officer effective April 6, 2026. David Mauro, M.D., Ph.D. transitions out and will serve as advisor through May 29, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
5 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.8% daily ATR makes tight stops impractical. Position-size conservatively.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $3.52: Quality below floor (2.0 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.1/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 35%; Below-average business quality; Negative price momentum. Chart setup: RSI 57 mid-range, Bollinger mid-band. Prior stop was $3.28. Score 4.1/10, moderate confidence.
Take-profit target: $5.84 (+65.7% upside). Prior stop was $3.28. Stop-loss: $3.28.
Concentration risk — Customer: Roche and Genentech, Takeda, and Bayer; Quality below floor (2.0 < 4.0); Value-trap signals (2/5): High leverage (D/E 3.8), Material insider selling (3 sells, 13.86% of cap).
Recursion Pharmaceuticals, Inc. trades at a P/E of N/A (forward -3.6). TrendMatrix value score: 5.4/10. Verdict: Sell.
14 analysts cover RXRX with a consensus score of 3.7/5. Average price target: $7.
What does Recursion Pharmaceuticals, Inc. do?Recursion Pharmaceuticals is a clinical-stage TechBio company using its AI-native Recursion OS platform for drug...
Recursion Pharmaceuticals is a clinical-stage TechBio company using its AI-native Recursion OS platform for drug discovery spanning biology, chemistry, and clinical development. Revenue is primarily from funded R&D collaboration agreements with Roche/Genentech, Takeda, and Bayer; accumulated deficit of $2.1B as of December 31, 2025.